Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Biofrontera AG
  6. News
  7. Summary
    B8F   DE0006046113

BIOFRONTERA AG

(B8F)
  Report
Delayed Xetra  -  11:36 2022-09-30 am EDT
1.465 EUR   +2.45%
09/06Biofrontera Obtains Notice of Allowance for US Patent Related to Nanoemulsion Technology
MT
08/25Biofrontera AG Appoints Prof. Dr. Karin Lergenmüller to the Supervisory Board
CI
08/19Biofrontera AG Announces Appointment of Pilar de la Huerta Martinez as New Chief Financial Officer
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PTA-News: Biofrontera AG: Employees appeal in own statement to the shareholders not to accept the takeover offer of Deutsche Balaton AG

08/03/2022 | 04:36am EDT

Business news for the stock market

Leverkusen, Germany (pta017/03.08.2022/10:30) - - Employees take a stand on the takeover offer of Deutsche Balaton AG published on July 15, 2022

- Employees appeal to the shareholders of Biofrontera AG NOT to accept the takeover offer

Biofrontera AG (ISIN: DE0006046113), an international biopharmaceutical company, announces that the employees of the Biofrontera Group have issued their own statement on the takeover offer of Deutsche Balaton AG pursuant to Section 27 (2) WpÜG. In this statement, 88 employees (representing 100% of the active employees in Germany) appeal to the shareholders of Biofrontera AG NOT to accept the takeover offer of Deutsche Balaton AG published on July 15, 2022, and at the same time take a position on the election proposals for the elections to the Supervisory Board for the Annual General Meeting on August 23, 2022.

The statement of the employees was attached on August 3, 2022 to the statement of the Management Board, which the Management Board submitted together with the Supervisory Board, and was published on the internet on the website of Biofrontera AG at http://www.biofrontera.com in the section "Investors" under "Takeover Offer of Deutsche Balaton AG".

https://www.biofrontera.com/en/investors/takeover-offer-of-deutsche-balaton-ag

-END-

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Leverkusen-based company develops and markets innovative products for the treatment, protection and care of the skin. Its key products include Ameluz®, a prescription drug for the treatment of non-melanoma skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the USA since May 2016. In Europe, the company also markets the Belixos® dermocosmetic series, a specialty care product for damaged skin. Biofrontera is one of a few German pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on US OTC market (BFAGY). www.biofrontera.com

Forward-looking statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as "anticipate", "believe", "predict", "estimate" and "intend", among others. Such forward-looking statements are based on current estimates and assumptions made by Biofrontera AG's management to the best of its knowledge and belief, which in their opinion are reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, financial condition, performance or achievements of the company or industry to be materially different from any future results, financial condition, performance or achievements expressed or implied by such forward-looking statements. No undue reliance should be placed on such statements. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statements.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate
other stock exchanges: US OTC

[ source: https://www.pressetext.com/news/20220803017 ]

Disclaimer

Biofrontera AG published this content on 03 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 August 2022 08:35:04 UTC.


© Publicnow 2022
All news about BIOFRONTERA AG
09/06Biofrontera Obtains Notice of Allowance for US Patent Related to Nanoemulsion Technolog..
MT
08/25Biofrontera AG Appoints Prof. Dr. Karin Lergenmüller to the Supervisory Board
CI
08/19Biofrontera AG Announces Appointment of Pilar de la Huerta Martinez as New Chief Financ..
CI
08/19Pta-news : Biofrontera AG: Biofrontera extends appointment of Management Board member Paul..
PU
08/19Biofrontera AG Extends Appointment of Management Board Member Paul Böckmann
CI
08/18Pta-news : Biofrontera AG: Biofrontera reports financial results for the six months ended ..
PU
08/18Biofrontera AG Provides Earnings Guidance for the Full Year of 2022
CI
08/17Pta-dd : Biofrontera AG: Managers' transactions announcement according to article 19 MAR
PU
08/12Earnings Flash (BFRI) BIOFRONTERA Posts Q2 Revenue $4.5M, vs. Street Est of $4.54M
MT
08/10Pta-news : Biofrontera AG: The request to convene an extraordinary shareholders' meeting b..
PU
More news
Financials
Sales 2022 26,2 M 25,7 M 25,7 M
Net income 2022 -38,1 M -37,4 M -37,4 M
Net Debt 2022 - - -
P/E ratio 2022 -2,44x
Yield 2022 -
Capitalization 83,1 M 81,5 M 81,5 M
Capi. / Sales 2022 3,17x
Capi. / Sales 2023 2,72x
Nbr of Employees 98
Free-Float 43,4%
Chart BIOFRONTERA AG
Duration : Period :
Biofrontera AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOFRONTERA AG
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,47 €
Average target price 2,80 €
Spread / Average Target 91,1%
EPS Revisions
Managers and Directors
Maria del Pilar de la Huerta Martinez Chief Financial Officer
Wilhelm Konrad Zours Chairman-Supervisory Board
Heikki Lanckriet Member-Supervisory Board
Helge Lubenow Member-Supervisory Board
Karlheinz Schmelig Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BIOFRONTERA AG-1.01%81
CSL LIMITED-1.96%88 546
SAMSUNG BIOLOGICS CO.,LTD.-10.63%39 998
BIOGEN INC.11.29%38 745
WUXI BIOLOGICS (CAYMAN) INC.-48.78%25 758
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-30.63%19 438